‘Velcade’ generic market of KRW 20 billion will open next year
Boryung Pharm will enter competition of Velcade(bortezomib, Janssen Korea) generics, a blockbuster multiple myeloma treatment.
According to the Ministry of Food and Drug Safety and the industry concerned on the 17th, Boryung Pharm acquired domestic approval of ‘Velkin Inj 3.5mg.’
Indications of...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
